• Explore /
  • Poster
  • / A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult aubjects with advanced solid tumors.

A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult aubjects with advanced solid tumors.

Abstract Poster

Authors

null

Brendan D. Curti

Providence Cancer Center and Earle A. Chiles Research Institute, Portland, OR

Brendan D. Curti , Todd Michael Bauer , Neeltje Steeghs , A. Craig Lockhart , Francis J. Giles , John D. Powderly II, Naiyer A. Rizvi , Jonathan Wade Goldman , Samir Khleif , Matthew Joseph Gribbin , Jennifer T. McDevitt , Scott A Hammond , Victoria L Chiou , Aurelien Marabelle

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research,Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT02705482

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS3100)

DOI

10.1200/JCO.2017.35.15_suppl.TPS3100

Abstract #

TPS3100

Poster Bd #

190b

Abstract Disclosures

Similar Posters

First Author: Johanna C. Bendell

First Author: Margaret K. Callahan

First Author: Jiajian Liu

First Author: Aung Naing